The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Abstract
Two thousand three hundred and thirty two nonselected brains from 1- to 100-year-old individuals were examined using immunocytochemistry (AT8) and Gallyas silver staining for abnormal tau; immunocytochemistry (4G8) and Campbell-Switzer staining were used for the detection ofβ-amyloid. A total of 342 cases was negative in the Gallyas stain but when restaged for AT8 only 10 were immunonegative. Fifty-eight cases had subcortical tau predominantly in the locus coeruleus, but there was no abnormal cortical tau (subcortical Stages a-c). Cortical involvement (abnormal tau in neurites) was identified first in the transentorhinal region (Stage 1a, 38 cases). Transentorhinal pyramidal cells displayed pretangle material (Stage 1b, 236 cases). Pretangles gradually became argyrophilic neurofibrillary tangles (NFTs) that progressed in parallel with NFT Stages I to VI. Pretangles restricted to subcortical sites were seen chiefly at younger ages. Of the total cases, 1,031 (44.2%) had β-amyloid plaques. The first plaques occurred in the neocortex after the onset of tauopathy in the brainstem. Plaques generally developed in the 40s in 4% of all cases, culminating in their tenth decade (75%). β-amyloid plaques and NFTs were significantly correlated (p < 0.0001). These data suggest that tauopathy associated with sporadic Alzheimer disease may begin earlier than previously thought and possibly in the lower brainstem rather than in the transentorhinal region.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Up to 60% of CU individuals over age 80 years have AD neuropathologic changes at autopsy or by biomarkers [60,152,212–214].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [213]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“screening revealed low rates of Braak 1–2 NFT stages in all three groups (Table 2), consistent with literature-based norms [3].”
From Tuberous sclerosis complex is associated with a novel human tauopathy (2023) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It should be noted that tau aggregation in the brain is associated with older age and is generally uncommon in healthy young adults (Braak et al., 2011; Crary et al., 2014).”
From Tauopathy and Epilepsy Comorbidities and Underlying Mechanisms (2022) · cites this paper as Braak et al., 2011
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It is expected that many persons die with brains that exhibit AD neuropathologic change in the preclinical phase of AD; indeed, data support the modeled expectations (44, 142).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Medial temporal and brainstem neurofibrillary changes were observed in our older TSC subjects, as expected, but at a rate comparable to that observed in the epilepsy and non-neurological control groups and age-based norms [3].”
From Tuberous sclerosis complex is associated with a novel human tauopathy (2023) · cites this paper as [3]
In the citing paper
“In individuals with autosomal dominant mutations in genes coding for amyloid precursor protein (APP) or Presenilin 119 , alterations in Aβ generation that result in early deposition of plaque initiate the disease and patients invariably develop the full spectrum of tau pathology 120,121 .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [121]
In the citing paper
“NFTs first appear in layer II of the entorhinal cortex (EC) during AD onset.”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [231]
In the citing paper
“NFTs subsequently appear in interconnected anatomical regions within the brain, including the hippocampus and neocortex during neurodegenerative progression [229–231].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [231]
In the citing paper
“Furthermore, it impairs adult hippocampal neurogenesis in mice and affects cortical thickness, brain activity, and mitochondrial function well before significant Aβ accumulation in the human brains [74–76].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [76]
In the citing paper
“Most of all, this binary threshold does not reflect the reality of amyloid β and tau pathology, which is continuous and present at a minimal extent in almost all people older than 70 years,17 with important discrepancies between pathology burden and clinical symptoms at intermediate extents (panel 2).”
From Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (2021) · cites this paper as [17]
In the citing paper
“For tau biomarkers, there is also a strong discrepancy between neuropathological identification (in post-mortem studies, the presence of tau Braak stages I–II is almost universal after age 70 years)17,19 and in-vivo measures of tau aggregates on PET (36% of individuals are tau positive after the age of 70 years23).”
From Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (2021) · cites this paper as [17]
In the citing paper
“The concordance of genetics and Aβ deposition is aligned with CPC studies that indicate that AβPs may be a temporally “upstream” feature of the neocortical disease, with the caveats that brainstem and medial temporal lobe pretangles and NFTs are seen in subjects without Aβ deposition in all age categories (33, 39, 44).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
In the citing paper
“In contrast to NFTs, AβPs are extracellular (45, 46) and are found in a high proportion of all elderly persons but are not universal (44, 47, 48).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
In the citing paper
“Recently, it has been reported that NFTs are also very common in certain brainstem nuclei in subjects without dementia (39-44).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
In the citing paper
“Neurofibrillary pathology is observed in the human brain long before Aβ plaques develop (39, 44, 300).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
In the citing paper
“Neuritic plaques seem to develop after diffuse AβPs and NFTs (44).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
In the citing paper
“At 40 years, all individuals studied by Braak and Del Tredici (39) and Braak et al (44) exhibited at least initial neurofibrillary pathology in the brainstem (Fig. 5).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 2×
“The first lesions were usually seen in the transentorhinal region (2).”
BackgroundSelf-citationThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Aston-Jones, G., & Cohen, J. D. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135709 · Cited by 4,472
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Self-citationBraak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Self-citationA Century of Alzheimer's Disease
Goedert, M., & Spillantini, M. G. (2006) · Science · doi:10.1126/science.1132814 · Cited by 2,153
The locus coeruleus and noradrenergic modulation of cognition
Sara, S. J. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2573 · Cited by 1,848
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Self-citation
Cited by
Sorted by citations
Items 201–300 of 1,010
Lipid lowering and Alzheimer disease risk: A mendelian randomization study
Williams, D. M., Finan, C., Schmidt, A. F., Burgess, S., & Hingorani, A. D. (2020) · Annals of Neurology · doi:10.1002/ana.25642 · Cited by 157
Neurodegenerative Disease Tauopathies
Creekmore, B. C., Watanabe, R., & Lee, E. B. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-120750 · Cited by 155
Locus Coeruleus Activity Strengthens Prioritized Memories Under Arousal
Clewett, D. V., Huang, R., Velasco, R., Lee, T.-H., & Mather, M. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.2097-17.2017 · Cited by 152
Dystrophic microglia in late‐onset Alzheimer's disease
Streit, W. J., Khoshbouei, H., & Bechmann, I. (2020) · Glia · doi:10.1002/glia.23782 · Cited by 152
Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy
Ossenkoppele, R., Schonhaut, D. R., Baker, S. L., O’Neil, J. P., Janabi, M., Ghosh, P. M., Santos‐Santos, M., Miller, Z., Bettcher, B. M., Gorno‐Tempini, M. L., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24321 · Cited by 151
Can Infections Cause Alzheimer's Disease?
Mawanda, F., & Wallace, R. B. (2013) · Epidemiologic Reviews · doi:10.1093/epirev/mxs007 · Cited by 151
Millan, M. J. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.004 · Cited by 151
Katsumoto, A., Takeuchi, H., & Tanaka, F. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00980 · Cited by 151
Niu, L., Zhang, F., Xu, X., Yang, Y., Li, S., Liu, H., & Le, W. (2021) · Brain Pathology · doi:10.1111/bpa.13028 · Cited by 151
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
Leuzy, A., Smith, R., Cullen, N. C., Strandberg, O., Vogel, J. W., Binette, A. P., Borroni, E., Janelidze, S., Ohlsson, T., Jögi, J., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4654 · Cited by 149
Derisbourg, M. J., Leghay, C., Chiappetta, G., Fernández-Gómez, F.-J., Laurent, C., Demeyer, D., Carrier, S., Buée‐Scherrer, V., Blum, D. L., Vinh, J., et al. (2015) · Scientific Reports · doi:10.1038/srep09659 · Cited by 149
Dahl, M. J., Mather, M., Werkle‐Bergner, M., Kennedy, B. L., Guzman, S. J., Hurth, K. M., Miller, C. A., Qiao, Y., Shi, Y., Chui, H. C., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.11.006 · Cited by 149
Braak, H., Zetterberg, H., Tredici, K. D., & Blennow, K. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1139-0 · Cited by 148
Self-citationHou, X., Fiesel, F. C., Truban, D., Castanedes Casey, M., Lin, W.-L., Soto, A. I., Tacik, P., Rousseau, L. G., Diehl, N. N., Heckman, M. G., et al. (2018) · Autophagy · doi:10.1080/15548627.2018.1461294 · Cited by 147
Kang, J., Korecka, M., Toledo, J. B., Trojanowski, J. Q., & Shaw, L. M. J. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.202937 · Cited by 147
Pupillary Responses as a Biomarker of Early Risk for Alzheimer’s Disease
Granholm, E. L., Panizzon, M. S., Elman, J. A., Jak, A. J., Hauger, R. L., Bondi, M. W., Lyons, M. J., Franz, C. E., & Kremen, W. S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161078 · Cited by 147
Alzheimer's Disease: A Clinical and Basic Science Review
Korolev, I. O. (2014) · Cited by 146
Calderón‐Garcidueñas, L., González-Maciel, A., Reynoso-Robles, R., Delgado‐Chávez, R., Mukherjee, P. S., Kulesza, R. J., Torres‐Jardón, R., Ávila-Ramírez, J., & Villarreal-Ríos, R. (2018) · Environmental Research · doi:10.1016/j.envres.2018.03.023 · Cited by 146
Davidson, Y. S., Robinson, A., Prasher, V. P., & Mann, D. M. A. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0559-4 · Cited by 146
Egroo, M. V., Koshmanova, E., Vandewalle, G., & Jacobs, H. I. L. (2022) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2022.101592 · Cited by 146
Calderón‐Garcidueñas, L., Kulesza, R. J., Doty, R. L., D’Angiulli, A., & Torres‐Jardón, R. (2014) · Environmental Research · doi:10.1016/j.envres.2014.12.012 · Cited by 145
Malia, T., Teplyakov, A., Ernst, R., Wu, S., Lacy, E. R., Liu, X., Vandermeeren, M., Mercken, M. H., Luo, J., Sweet, R. W., et al. (2016) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24988 · Cited by 144
Knopman, D. S., Haeberlein, S. B., Carrillo, M. C., Hendrix, J. A., Kerchner, G., Margolin, R. A., Maruff, P. T., Miller, D. S., Tong, G., Tome, M. B., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.03.002 · Cited by 144
Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration
Thomas, K. R., Bangen, K. J., Weigand, A. J., Edmonds, E. C., Wong, C. G., Cooper, S., Delano‐Wood, L., Bondi, M. W., & Initiative, A. D. N. (2019) · Neurology · doi:10.1212/wnl.0000000000008838 · Cited by 144
The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases
Nelson, P. T., Abner, E. L., Patel, E., Anderson, S., Wilcock, D. M., Kryscio, R. J., Eldik, L. J. V., Jicha, G. A., Gal, Z. T., Nelson, R. S., et al. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx099 · Cited by 141
Mechanobiology of the brain in ageing and Alzheimer's disease
Hall, C. M., Moeendarbary, E., & Sheridan, G. K. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14766 · Cited by 140
The aged rhesus macaque manifests Braak stage III/IV Alzheimer's‐like pathology
Paspalas, C. D., Carlyle, B. C., Leslie, S., Preuss, T. M., Crimins, J. L., Huttner, A. J., van Dyck, C. H., Rosene, D. L., Nairn, A. C., & Arnsten, A. F. T. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.11.005 · Cited by 140
Chen, X., Huddleston, D. E., Langley, J. A., Ahn, S., Barnum, C. J., Factor, S. A., Levey, A. I., & Hu, X. P. (2014) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2014.07.003 · Cited by 140
cAMP-PKA phosphorylation of tau confers risk for degeneration in aging association cortex
Carlyle, B. C., Nairn, A. C., Wang, M., Yang, Y., Jin, L. E., Simen, A. A., Ramos, B. P., Bordner, K. A., Craft, G. E., Davies, P., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322360111 · Cited by 139
α1-Adrenergic Receptors in Neurotransmission, Synaptic Plasticity, and Cognition
Perez, D. M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.581098 · Cited by 139
Altered synapses and gliotransmission in Alzheimer's disease and AD model mice
Mitew, S., Kirkcaldie, M. T. K., Dickson, T. C., & Vickers, J. C. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.010 · Cited by 138
Aged chimpanzees exhibit pathologic hallmarks of Alzheimer's disease
Edler, M. K., Sherwood, C. C., Meindl, R. S., Hopkins, W. D., Ely, J. J., ERWIN, J. M., Mufson, E. J., Hof, P. R., & Raghanti, M. A. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.07.006 · Cited by 138
Wirth, M., Haase, C. M., Villeneuve, S., Vogel, J. W., & Jagust, W. J. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.02.015 · Cited by 138
Chalermpalanupap, T., Schroeder, J. P., Rorabaugh, J. M., Liles, L. C., Lah, J. J., Levey, A. I., & Weinshenker, D. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.1483-17.2017 · Cited by 136
Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology
Ling, H., Kovács, G. G., Vonsattel, J. P., Davey, K., Mok, K. Y., Hardy, J., Morris, H. R., Warner, T. T., Holton, J. L., & Révész, T. (2016) · Brain · doi:10.1093/brain/aww256 · Cited by 136
Microglial Malfunction: The Third Rail in the Development of Alzheimer's Disease
Mhatre, S. D., Tsai, C. A., Rubin, A. J., James, M. L., & Andreasson, K. I. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.08.006 · Cited by 134
Chiu, C., Miller, M. C., Monahan, R., Osgood, D. P., Stopa, E. G., & Silverberg, G. D. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.05.020 · Cited by 134
Theofilas, P., Ehrenberg, A. J., Nguy, A. K., Thackrey, J. M., Dunlop, S. R., Mejia, M. B., Alho, A. T. D. L., Leite, R. E. P., Rodriguez, R. D., Suemoto, C. K., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.09.007 · Cited by 134
Polanco, J. C., Hand, G. R., Briner, A., Li, C., & Götz, J. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02254-3 · Cited by 134
Chronic Traumatic Encephalopathy: Historical Origins and Current Perspective
Montenigro, P. H., Stein, T. D., Cantu, R. C., & Stern, R. A. (2015) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032814-112814 · Cited by 133
Kurbatskaya, K., Phillips, E. C., Croft, C. L., Dentoni, G., Hughes, M. M., Wade, M. A., Al‐Sarraj, S., Troakes, C., O’Neill, M. J., Perez‐Nievas, B. G., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0299-2 · Cited by 133
Esposito, R., Cieri, F., Chiacchiaretta, P., Cera, N., Lauriola, M., Giannantonio, M. D., Tartaro, A., & Ferretti, A. (2017) · Brain Imaging and Behavior · doi:10.1007/s11682-017-9686-y · Cited by 133
Baker, S. L., Harrison, T. M., Maass, A., La Joie, R., & Jagust, W. J. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224113 · Cited by 132
Interaction between pathogenic proteins in neurodegenerative disorders
Jellinger, K. A. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01507.x · Cited by 132
Braak, H., & Tredici, K. D. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a023630 · Cited by 132
Self-citationCalderón‐Garcidueñas, L., Franco-Lira, M., Mora-Tiscareño, A., Medina‐Cortina, H., Torres‐Jardón, R., & Kavanaugh, M. (2013) · BioMed Research International · doi:10.1155/2013/161687 · Cited by 131
Urrutia, P. J., Bórquez, D. A., & Núñez, M. T. (2021) · Antioxidants · doi:10.3390/antiox10010061 · Cited by 131
Regional amyloid accumulation and cognitive decline in initially amyloid-negative adults
Farrell, M. E., Chen, X., Rundle, M. M., Chan, M. Y., Wig, G. S., & Park, D. C. (2018) · Neurology · doi:10.1212/wnl.0000000000006469 · Cited by 130
Liu, K. Y., Kievit, R., Tsvetanov, K. A., Betts, M. J., Düzel, E., Rowe, J. B., Cam-CAN, TYLER, L. K., Brayne, C., Bullmore, E. T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15410-w · Cited by 132
Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease
Thomas, J. B., Brier, M. R., Bateman, R. J., Snyder, A. Z., Benzinger, T. L., Xiong, C., Raichle, M., Holtzman, D. M., Sperling, R. A., Mayeux, R., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1654 · Cited by 129
Spatial proteomics in three-dimensional intact specimens
Bhatia, H. S., Brunner, A.-D., Öztürk, F., Kapoor, S., Rong, Z., Mai, H., Thielert, M., Ali, M., Al-Maskari, R., Paetzold, J. C., et al. (2022) · Cell · doi:10.1016/j.cell.2022.11.021 · Cited by 129
Cortical Odor Processing in Health and Disease
Wilson, D. A., Xu, W., Sadrian, B., Courtiol, E., Cohen, Y., & Barnes, D. C. (2014) · Progress in brain research · doi:10.1016/b978-0-444-63350-7.00011-5 · Cited by 129
Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers
Casaletto, K. B., Elahi, F. M., Bettcher, B. M., Neuhaus, J. M., Bendlin, B. B., Asthana, S., Johnson, S. C., Yaffe, K. S., Carlsson, C. M., Blennow, K., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004569 · Cited by 128
Synaptic tau: A pathological or physiological phenomenon?
Robbins, M., Clayton, E. L., & Schierle, G. S. K. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01246-y · Cited by 128
In vivo rate-determining steps of tau seed accumulation in Alzheimer’s disease
Meisl, G., Hidari, E., Allinson, K., Rittman, T., DeVos, S. L., Sanchez, J. S., Xu, C. K., Duff, K. E., Johnson, K. A., Rowe, J. B., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh1448 · Cited by 127
Neuroinflammatory Signals in Alzheimer Disease and APP/PS1 Transgenic Mice
López‐González, I., Schlüter, A., Aso, E., Garcia‐Esparcia, P., Ansoleaga, B., Llorens, F., Carmona, M., Moreno, J. R., Fuso, A., Portero‐Otín, M., et al. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000176 · Cited by 128
Thal, D. R., Tredici, K. D., Ludolph, A. C., Hoozemans, J. J. M., Rozemüller, A. J. M., Braak, H., & Knippschild, U. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0871-6 · Cited by 126
Self-citationGomes, L. A., Hipp, S. A., Rijal Upadhaya, A., Balakrishnan, K., Ospitalieri, S., Koper, M. J., Largo-Barrientos, P., Uytterhoeven, V., Reichwald, J., Rabe, S., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02053-5 · Cited by 125
Self-citationSchmidt, M. E., Chiao, P., Klein, G., Matthews, D. C., Thurfjell, L., Cole, P. E., Margolin, R. A., Landau, S. M., Foster, N. L., Mason, N. S., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.09.004 · Cited by 125
Unmasking selective path integration deficits in Alzheimer’s disease risk carriers
Bierbrauer, A., Kunz, L., Gomes, C. A., Luhmann, M., Deuker, L., Getzmann, S., Wascher, E., Gajewski, P. D., Hengstler, J. G., Fernandez-Alvarez, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba1394 · Cited by 125
Is late‐onset Alzheimer's disease really a disease of midlife?
Ritchie, K. A., Ritchie, C. W., Yaffe, K. S., Skoog, I. G., & Scarmeas, N. (2015) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.06.004 · Cited by 124
Early diagnosis and treatment of Alzheimer’s disease: new definitions and challenges
Pais, M. V., Martinez, L. D., Ribeiro, O. G., Loureiro, J. C., Fernandez, R., Valiengo, L. D. C. L., Canineu, P. R., Stella, F., Talib, L. L., Radanovic, M., et al. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0735 · Cited by 124
Kazim, S. F., & Iqbal, K. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0119-y · Cited by 126
Altered sleep and EEG power in the P301S Tau transgenic mouse model
Holth, J. K., Mahan, T. E., Robinson, G. O., da Rocha, A. S., & Holtzman, D. M. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.390 · Cited by 122
The effect of insomnia on development of Alzheimer’s disease
Sadeghmousavi, S., Eskian, M., Rahmani, F., & Rezaei, N. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01960-9 · Cited by 122
Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages
Pascoal, T. A., Benedet, A. L., Tudorascu, D., Therriault, J., Mathotaarachchi, S. S., Savard, M., Lussier, F. Z., Tissot, C., Chamoun, M., Kang, M. S., et al. (2021) · Brain · doi:10.1093/brain/awab248 · Cited by 122
Iatrogenic Creutzfeldt-Jakob disease with Amyloid-β pathology: an international study
Calì, I., Cohen, M. L., Haı̈k, S., Parchi, P., Giaccone, G., Collins, S. J., Kofskey, D., Wang, H., McLean, C., Brandel, J., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0503-z · Cited by 121
Norepinephrine metabolite DOPEGAL activates AEP and pathological Tau aggregation in locus coeruleus
Kang, S. S., Liu, X., Ahn, E. H., Xiang, J., Manfredsson, F. P., Yang, X., Luo, H. R., Liles, L. C., Weinshenker, D., & Ye, K. (2019) · Journal of Clinical Investigation · doi:10.1172/jci130513 · Cited by 121
Kobro-Flatmoen, A., Lagartos-Donate, M. J., Aman, Y., Edison, P., Witter, M. P., & Fang, E. F. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101307 · Cited by 119
Theofilas, P., Dunlop, S. R., Heinsen, H., & Grinberg, L. T. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142682 · Cited by 119
Olfactory Receptors in Non-Chemosensory Organs: The Nervous System in Health and Disease
Ferrer, I., Garcia‐Esparcia, P., Carmona, M., Carro, E., Aronica, E., Kovács, G. G., Grison, A., & Gustincich, S. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00163 · Cited by 118
Amyloid-β accumulation in the CNS in human growth hormone recipients in the UK
Ritchie, D. L., Adlard, P., Peden, A., Lowrie, S., Grice, M. L., Burns, K., Jackson, R. J., Yull, H. M., Keogh, M. J., Wei, W., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1703-0 · Cited by 118
Calderón‐Garcidueñas, L., Herrera-Soto, A., Jury, N., Maher, B. A., González-Maciel, A., Reynoso-Robles, R., Ruiz-Rudolph, P., van Zundert, B., & Varela‐Nallar, L. (2020) · Environmental Research · doi:10.1016/j.envres.2020.109226 · Cited by 118
Korecka, M., Waligórska, T., Figurski, M., Toledo, J. B., Arnold, S. E., Grossman, M., Trojanowski, J. Q., & Shaw, L. M. J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132489 · Cited by 117
Lateral Entorhinal Modulation of Piriform Cortical Activity and Fine Odor Discrimination
Chapuis, J., Cohen, Y., He, X., Zhang, Z., Jin, S., Xu, F., & Wilson, D. A. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1387-13.2013 · Cited by 117
Devos, H., Gustafson, K. M., Ahmadnezhad, P., Liao, K., Mahnken, J. D., Brooks, W. M., & Burns, J. M. (2020) · Brain Sciences · doi:10.3390/brainsci10120994 · Cited by 115
Iatrogenic Alzheimer’s disease in recipients of cadaveric pituitary-derived growth hormone
Banerjee, G., Farmer, S. F., Hyare, H., Jaunmuktane, Z., Mead, S., Ryan, N. S., Schott, J. M., Werring, D. J., Rudge, P., & Collinge, J. (2024) · Nature Medicine · doi:10.1038/s41591-023-02729-2 · Cited by 115
Hammerschmidt, T., Kummer, M. P., Terwel, D., Martinez, A., Gorji, A., Pape, H., Rommelfanger, K. S., Schroeder, J. P., Stoll, M., Schultze, J. L., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.013 · Cited by 115
The dendritic hypothesis for Alzheimer's disease pathophysiology
Cochran, J. N., Hall, A. M., & Roberson, E. D. (2014) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2013.12.004 · Cited by 114
Locus coeruleus at asymptomatic early and middle Braak stages of neurofibrillary tangle pathology
Andrés‐Benito, P., Fernández‐Dueñas, V., Carmona, M., Escobar, L. A., Torrejón-Escribano, B., Aso, E., Ciruela, F., & Ferrer, I. (2017) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12386 · Cited by 114
Alzheimer's disease including focal presentations
Villain, N., & Dubois, B. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1681041 · Cited by 113
Leboucher, A., Laurent, C., Fernández-Gómez, F.-J., Burnouf, S., Troquier, L., Eddarkaoui, S., Demeyer, D., Caillierez, R., Zommer, N., Vallez, E., et al. (2012) · Diabetes · doi:10.2337/db12-0866 · Cited by 113
Walker, L. C. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-3025 · Cited by 113
Kontsekova, E., Zilka, N., Kovacech, B., Skrabana, R., & Novak, M. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt277 · Cited by 112
Tau-Based Therapeutics for Alzheimer’s Disease: Active and Passive Immunotherapy
Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., Tortelli, R., Galizia, I., Prete, C., Daniele, A., et al. (2016) · Immunotherapy · doi:10.2217/imt-2016-0019 · Cited by 113
Distinct Therapeutic Mechanisms of Tau Antibodies
Funk, K. E., Mirbaha, H., Jiang, H., Holtzman, D. M., & Diamond, M. I. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.657924 · Cited by 111
Bell, W. R., An, Y., Kageyama, Y., English, C., Rudow, G. L., Pletnikova, O., Thambisetty, M., O'Brien, R., Moghekar, A. R., Albert, M. S., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.215 · Cited by 111
Defining the earliest pathological changes of Alzheimer's disease
Vickers, J. C., Mitew, S., Woodhouse, A., Fernández-Martos, C. M., Kirkcaldie, M. T., Canty, A. J., McCormack, G. H., & King, A. E. (2015) · Current Alzheimer Research · doi:10.2174/1567205013666151218150322 · Cited by 111
Kam, K., Parekh, A., Sharma, R. A., Andrade, A. G., Lewin, M. P., Castillo, B., Bubu, O. M., Chua, N. J., Miller, M. D., Mullins, A. E., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0309-5 · Cited by 111
Woodling, N. S., Colas, D., Wang, Q., Minhas, P. S., Panchal, M., Liang, X., Mhatre, S. D., Brown, H. D., Ko, N., Zagol-Ikapitte, I. A., et al. (2016) · Brain · doi:10.1093/brain/aww117 · Cited by 111
Calderón-Garcidueñas, L., González-Maciel, A., Reynoso-Robles, R., Kulesza, R. J., Mukherjee, P. S., Torres-Jardón, R., Rönkkö, T., & Doty, R. L. (2018) · Environmental Research · doi:10.1016/j.envres.2018.06.027 · Cited by 110
Tau biology, tauopathy, traumatic brain injury, and diagnostic challenges
Castellani, R. J., & Perry, G. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180721 · Cited by 110
Alzheimer's disease: Pathogenesis and prevention
Braak, H., & Tredici, K. D. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.01.011 · Cited by 110
Self-citationTosun, D., Landau, S. M., Aisen, P. S. S., Petersen, R. C., Mintun, M. A., Jagust, W., Weiner, M. W., & Initiative, A. D. N. (2017) · Brain · doi:10.1093/brain/awx046 · Cited by 110
Chronic Sleep Disruption Advances the Temporal Progression of Tauopathy in P301S Mutant Mice
Zhu, Y., Zhan, G., Fenik, P., Brandes, M., Bell, P., François, N., Shulman, K., & Veasey, S. C. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.0275-18.2018 · Cited by 110
Takahashi, J., Shibata, T., Sasaki, M., Kudo, M., Yanezawa, H., Obara, S., Kudo, K., Ito, K., Yamashita, F., & Terayama, Y. (2014) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.12280 · Cited by 110
Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation
Grinberg, L. T., Wang, X., Wang, C., Sohn, P., Theofilas, P., Sidhu, M., Arevalo, J. B., Heinsen, H., Huang, E. J., Rosen, H. J., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1080-2 · Cited by 110
Chiarini, A., Armato, U., Gardenal, E., Gui, L., & Prà, I. D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00217 · Cited by 109
Betts, M. J., Cárdenas‐Blanco, A., Kanowski, M., Spottke, A. E., Teipel, S. J., Kilimann, I., Jessen, F., & Düzel, E. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.02.001 · Cited by 109
Kang, J., Vanderstichele, H., Trojanowski, J. Q., & Shaw, L. M. J. (2012) · Methods · doi:10.1016/j.ymeth.2012.03.023 · Cited by 109
Metadata
- Authors
- Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K.
- Affiliations
- The University of Queensland (AU)
- Corresponding author
- Braak, Heiko
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-11
- Volume
- 70
- Issue
- 11
- Pages
- 960-969
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- OpenAlex
- W1993023011
- Cited by
- 2,194
- References
- 75
- Citations by year
- 2026: 152 · 2025: 192 · 2024: 260 · 2023: 233 · 2022: 192 · 2021: 235 · 2020: 182 · 2019: 144 · 2018: 121 · 2017: 110 · 2016: 100 · 2015: 85 · 2014: 78 · 2013: 65 · 2012: 42
- FWCI
- 41.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Neuropathology & Experimental Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer Forschung Initiative (10810)
- Deutsche Forschungsgemeinschaft (TH624 4–1)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, pathological staging, tauopathy, neurofibrillary tangles, amyloid plaques, locus coeruleus, brainstem, sporadic Alzheimer's disease, AT8 antibody
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Alzheimer Disease, Brain, Child, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, Neurons, Cohort Studies, Amyloid beta-Peptides, Silver Staining, Neurofibrillary Tangles, tau Proteins, Disease Progression, Statistics, Nonparametric, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
